section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: QRS interval prolongation, arrhythmias, bradycardia, CARDIAC ARREST, heart block.

Derm: photosensitivity, rash (higher incidence in children, patients taking valproic acid, high initial doses, or rapid dose increases), DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN).

EENT: blurred vision, double vision, rhinitis.

GI: nausea, vomiting, HEPATIC FAILURE.

GU: vaginitis.

Hemat: HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.

MS: arthralgia.

Neuro: ataxia, dizziness, headache, ASEPTIC MENINGITIS, behavior changes, depression, drowsiness, insomnia, SUICIDAL THOUGHTS, tremor.

Interactions

Drug-Drug:

Availability

(Generic available)

Route/Dosage

see Calculator

Epilepsy

In Combination with Other Antiepileptic Agents

Bipolar Disorder

Escalation Regimen

US Brand Names

LaMICtal, LaMICtal ODT, LaMICtal XR, Subvenite

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: anticonvulsants

Pharmacokinetics

Absorption: 98% absorbed following oral administration.

Distribution: Highly bound to melanin-containing tissues (eyes, pigmented skin).

Metabolism/Excretion: Mostly metabolized by the liver via glucuronidation to inactive metabolites; 10% excreted unchanged by the kidneys.

Half-life: Children taking enzyme–inducing anticonvulsants: 7–10 hr; Children taking enzyme inducers and valproic acid: 15–27 hr; Children taking valproic acid: 44–94 hr; Adults: 25.4 hr (during chronic therapy of lamotrigine alone).

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown1.4–4.8 hr; 4–10 hr (XR)unknown

Patient/Family Teaching

Pronunciation

la-MOE-tri-jeen audio

Code

NDC Code*